# **Product data sheet**



MedKoo Cat#: 555297		
Name: BMS-955176 free base		/ 0
CAS#: 1392312-45-6 (free base)		₩, S=0
Chemical Formula: C <sub>42</sub> H <sub>62</sub> N <sub>2</sub> O <sub>4</sub> S		( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
Exact Mass: 690.443		
Molecular Weight: 691.028		H H
Product supplied as:	Powder	
Purity (by HPLC):	≥ 98%	] [ Y ] H
Shipping conditions	Ambient temperature	] HO
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years.	Ů
	In solvent: -80°C 3 months; -20°C 2 weeks.	

### 1. Product description:

GSK3532795, also known as BMS-955176, is a second-generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. GSK3532795 combines broad coverage of polymorphic viruses (EC50 <15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic profile in preclinical species.

### 2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	TBD	TBD

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.45 mL	7.24 mL	14.47 mL
5 mM	0.29 mL	1.45 mL	2.89 mL
10 mM	0.14 mL	0.72 mL	1.45 mL
50 mM	0.03 mL	0.14 mL	0.29 mL

### 5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

## **6. Recommended literature which reported protocols for in vitro and in vivo study** In vitro study

1. Dicker I, Zhang S, Ray N, Beno BR, Regueiro-Ren A, Joshi S, Cockett M, Krystal M, Lataillade M. Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. PLoS One. 2019 Oct 17;14(10):e0224076. doi: 10.1371/journal.pone.0224076. Erratum in: PLoS One. 2019 Nov 5;14(11):e0224976. PMID: 31622432; PMCID: PMC6797179. 2. Ray N, Li T, Lin Z, Protack T, van Ham PM, Hwang C, Krystal M, Nijhuis M, Lataillade M, Dicker I. The Second-Generation

2. Ray N, Li 1, Lin Z, Protack 1, van Ham PM, Hwang C, Krystal M, Nijhuis M, Lataillade M, Dicker I. The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates. J Acquir Immune Defic Syndr. 2017 May 1;75(1):52-60. doi: 10.1097/QAI.00000000001304. PMID: 28234686; PMCID: PMC5389583.

In vivo study

TBD

#### 7. Bioactivity

Biological target:

GSK3532795 (BMS-955176) is a potent, second-generation HIV-1 maturation inhibitor, with EC50s of 1.9, 10.2, 2.7 and 13 nM for HIV-1 WT, HIV-1 WT(human serum), HIV-1 V370A, and HIV-1  $\Delta$ V370, respectively.

## Product data sheet



### In vitro activity

Longitudinal clinical isolates from 15 PI-treated patients and 7 highly PI-resistant (nonlongitudinal) viruses containing major and minor PI resistance-associated mutations were evaluated for GSK3532795 sensitivity. All nonlongitudinal viruses tested were sensitive to GSK3532795 (FC-IC50 range 0.16-0.68). Among longitudinal isolates, all post-PI treatment samples had major PI resistance-associated mutations in PR and 17/21 had PI resistance-associated changes in Gag. Nineteen of the 21 post-PI treatment samples had GSK3532795 CFB <3. Median (range) CFB was 0.83 (0.05-27.4) [Monogram (11 patients)] and 1.5 (1.0-2.2) [single-cycle (4 patients)]. The 2 post-PI treatment samples showing GSK3532795 CFB >3 (Monogram) were retested using single- and multiple-cycle assays. In conclusion, GSK3532795 maintained antiviral activity against PI-resistant isolates with emergent PR and/or Gag mutations. This finding supports continued development of GSK3532795 in treatment-experienced patients with or without previous PI therapy.

Reference: J Acquir Immune Defic Syndr. 2017 May 1;75(1):52-60. https://pubmed.ncbi.nlm.nih.gov/28234686/

In vivo activity

**TBD** 

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.